Showing 5181-5190 of 5693 results for "".
- Sleep Apnea Linked to Blinding Eye Disease in People with Diabeteshttps://modernod.com/news/sleep-apnea-linked-to-blinding-eye-disease-in-people-with-diabetes/2477016/New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes
- Using AI to Screen for Diabetic Eye Disease Feasible in the Real Worldhttps://modernod.com/news/using-ai-to-screen-for-diabetic-eye-disease-feasible-in-the-real-world/2477017/New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist and it can provide a reading in 60 seconds, making real-time screening possible f
- Luneau Technology Acquires Next Sight to Enter Telehealth Markethttps://modernod.com/news/luneau-technology-acquires-next-sight-to-enter-telehealth-market/2477007/Luneau Technology group announced that it has acquired Padova, Italy-based Next Sight, maker of the Nexy retinal screening device. Terms of the deal were not disclosed. The acquisition brings to Luneau increased capabilities–covering both back and front of the eye. Luneau develops,
- Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the UShttps://modernod.com/news/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/2477008/Sun Pharmaceutical announced that its dry eye drug Cequa (cyclosporine ophthalmic solution) 0.09% is now commercially available the United States. Cequa, which offers the highest concentration of cyclosporine for ophthalmic use approved by the FDA, is indicated to increase tear production in pati
- New Approach to Slowing Nearsightedness in Children Shows Promisehttps://modernod.com/news/new-approach-to-slowing-nearsightedness-in-children-shows-promise/2477006/Combining two different treatment methods to slow the progression of myopia may deliver better results than either can achieve on their own. A new, 2-year study shows that treating children with eye drops and contact lenses was 28 percent to 38 percent more effective in slowing myopia. The resear
- Antibody-based eye drops show promise for treating dry eye diseasehttps://modernod.com/news/antibody-based-eye-drops-show-promise-for-treating-dry-eye-disease/2477005/Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid. They are also the first to demonstrate that patients with dry eye d
- AAO: In-Office Gene Therapy for Wet AMD is Cominghttps://modernod.com/news/aao-in-office-gene-therapy-for-wet-amd-is-coming/2477002/Gene therapy is showing promise for one of the most common causes of blindness. Data presented on Friday show that six patients with wet age-related macular degeneration (AMD) have, so far, an average of 8 months without the need for continued injections to control a di
- Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVOhttps://modernod.com/news/kodiak-sciences-announces-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-wet-amd-dme-and-rvo/2477003/Kodiak Sciences announced promising safety, efficacy and durability data from its ongoing phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants